Reliable measurements of brain atrophy in individual patients with multiple sclerosis
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10328247" target="_blank" >RIV/00064165:_____/16:10328247 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/16:10328247
Výsledek na webu
<a href="http://dx.doi.org/10.1002/brb3.518" target="_blank" >http://dx.doi.org/10.1002/brb3.518</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/brb3.518" target="_blank" >10.1002/brb3.518</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Reliable measurements of brain atrophy in individual patients with multiple sclerosis
Popis výsledku v původním jazyce
Introduction: As neurodegeneration is recognized as a major contributor to disability in multiple sclerosis (MS), brain atrophy quantification could have a high added value in clinical practice to assess treatment efficacy and disease progression, provided that it has a sufficiently low measurement error to draw meaningful conclusions for an individual patient. Method: In this paper, we present an automated longitudinal method based on Jacobian integration for measuring whole-brain and gray matter atrophy based on anatomical magnetic resonance images (MRI), named MSmetrix. MSmetrix is specifically designed to measure atrophy in patients with MS, by including iterative lesion segmentation and lesion filling based on FLAIR and T1-weighted MRI scans. Results: MSmetrix is compared with SIENA with respect to test-retest error and consistency, resulting in an average test-retest error on an MS data set of 0.13% (MSmetrix) and 0.17% (SIENA) and a consistency error of 0.07% (MSmetrix) and 0.05% (SIENA). On a healthy subject data set including physiological variability the test-retest is 0.19% (MSmetrix) and 0.31% (SIENA). Conclusion: Therefore, we can conclude that MSmetrix could be of added value in clinical practice for the follow-up of treatment and disease progression in MS patients
Název v anglickém jazyce
Reliable measurements of brain atrophy in individual patients with multiple sclerosis
Popis výsledku anglicky
Introduction: As neurodegeneration is recognized as a major contributor to disability in multiple sclerosis (MS), brain atrophy quantification could have a high added value in clinical practice to assess treatment efficacy and disease progression, provided that it has a sufficiently low measurement error to draw meaningful conclusions for an individual patient. Method: In this paper, we present an automated longitudinal method based on Jacobian integration for measuring whole-brain and gray matter atrophy based on anatomical magnetic resonance images (MRI), named MSmetrix. MSmetrix is specifically designed to measure atrophy in patients with MS, by including iterative lesion segmentation and lesion filling based on FLAIR and T1-weighted MRI scans. Results: MSmetrix is compared with SIENA with respect to test-retest error and consistency, resulting in an average test-retest error on an MS data set of 0.13% (MSmetrix) and 0.17% (SIENA) and a consistency error of 0.07% (MSmetrix) and 0.05% (SIENA). On a healthy subject data set including physiological variability the test-retest is 0.19% (MSmetrix) and 0.31% (SIENA). Conclusion: Therefore, we can conclude that MSmetrix could be of added value in clinical practice for the follow-up of treatment and disease progression in MS patients
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NT13237" target="_blank" >NT13237: Klinické a paraklinické markery roztroušené sklerózy – korelace se současným stavem pacienta a predikce průběhu nemoci.</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Brain and Behavior
ISSN
2162-3279
e-ISSN
—
Svazek periodika
6
Číslo periodika v rámci svazku
9
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
12
Strana od-do
—
Kód UT WoS článku
000386128600012
EID výsledku v databázi Scopus
2-s2.0-84978712237